

YH/SE/29/2025-26
August 05, 2025

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1
G Block, Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051, India

Symbol: YATHARTH
ISIN: INE0JO301016

Dept. of Listing Operations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001, India

Scrip Code: 543950
ISIN: INE0JO301016

Subject: Outcome of Board Meeting - Financial Results & Others.

Dear Sir/Madam,

Pursuant to Regulation 30 & Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its meeting held today i.e. August 05, 2025, has inter-alia, consider and approved the following matters:

1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the first quarter ended June 30, 2025. The said financial results are enclosed herewith;
2. Appointment of Secretarial Auditor for a term of Five (5) years.

Pursuant to Regulation 24A(1A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board of Directors of the Company had appointed M/s MKP & Associates, Company Secretaries in whole-time practice (Firm registration number: S2011HR148000), as the Secretarial Auditor of the Company for a term of five (5) years commencing from April 1, 2025 till March 31, 2030, subject to approval of the Shareholders of the Company at the ensuing Annual General Meeting. The date of the Annual General Meeting shall be informed in the due course.

The detailed disclosure as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure A.

3. Re-appointment of Cost Auditor for the financial year 2025-26.

Re-appointment of M/s Subodh Kumar & Co. (SKC), Cost Accountants (Firm registration number: 104250) as the Cost Auditor of the Company, for the Financial Year 2025-26.

The detailed disclosure as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure B.

4. Appointment of Scrutinizer for AGM

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025
Tel: 011-49967892

Corporate Office

HO-01, Sector-01, Greater Noida West-201306
Tel: 0120-6811236 | Email: cs@yartharthhospitals.com
Web: www.yartharthhospitals.com

Our Hospitals

- 📍 Sector-110, Noida, Uttar Pradesh-201304
- 📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308
- 📍 Sector-01, Greater Noida West, Uttar Pradesh-201306
- 📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246
- 📍 Sector-88, Faridabad, Haryana-121002
- 📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009
- 📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

Pursuant to the provisions of Section 108 and Section 109 of the Companies Act, 2013, read with the Companies (Management and Administration) Rules, 2014, and other applicable provisions, if any, M/s Saurav Upadhyay & Associates, Company Secretaries (Firm Registration No. S2022DE852500), be and are hereby appointed as the Scrutinizer to conduct the scrutiny of the voting process, including remote e-voting and voting at the meeting, for the ensuing Annual General Meeting of the Company.

The above information will also be made available on website of the Company at <https://www.yatharthhospitals.com/investors>

The Board Meeting commenced at 01:15 PM (IST) and concluded at 01:50 PM (IST).

This is for your kind information and records.

Thanking You

Yours Faithfully,
For Yatharth Hospital & Trauma Care Services Limited

Dr. Ajay Kumar Tyagi
Chairman & Whole Time Director
DIN: 01792886

Encl.: A/a

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025
Tel: 011-49967892

Corporate Office

HO-01, Sector-01, Greater Noida West-201306
Tel: 0120-6811236 | Email: cs@yatharthhospitals.com
Web: www.yatharthhospitals.com

Our Hospitals

- 📍 Sector-110, Noida, Uttar Pradesh-201304
- 📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308
- 📍 Sector-01, Greater Noida West, Uttar Pradesh-201306
- 📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246
- 📍 Sector-88, Faridabad, Haryana-121002
- 📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009
- 📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

Annexure A

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations'), read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Details of Events	Information of such events(s)
a)	Reason for change viz., appointment, resignation, removal, death or otherwise;	Appointment of M/s MKP & Associates, Company Secretaries in practice (Firm registration number: S2011HR148000), as the Secretarial Auditor of the Company.
b)	Date of Appointment and term of appointment	The Board in its meeting held on August 05, 2025 has approved and recommended appointment of M/s MKP & Associates, Company Secretaries in practice as the Secretarial Auditor of the Company for a term of five (5) years who shall hold office from the conclusion of ensuing 18th Annual General Meeting until the conclusion of the 23rd Annual General Meeting for a period starting from April 1, 2025 to March 31, 2030.
c)	Brief profile (in case of appointment)	M/s. MKP & Associates (Company Secretaries) (hereinafter "the Firm") is a proprietorship firm managed by professionals having experience of 15 years in various fields of corporate law. The firm specialized in providing on going and ad hoc consultancy services, secretarial audit, due diligence, strategic planning etc. Clientele of the Firm is wide spread and have good exposure in handling and providing services to diversified clients such as Healthcare Sector, FMCG, Pharmaceutical industry, Liquor industry, Power Sector, MNCs, Section 8 Companies etc. The proprietor of the Firm has experience of appearing before regulatory authorities' viz. ROC, RD, NCLT on the behalf of clients.
d)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025
Tel: 011-49967892

Corporate Office

HO-01, Sector-01, Greater Noida West-201306
Tel: 0120-6811236 | Email: cs@yatharthhospitals.com
Web: www.yatharthhospitals.com

Our Hospitals

- 📍 Sector-110, Noida, Uttar Pradesh-201304
- 📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308
- 📍 Sector-01, Greater Noida West, Uttar Pradesh-201306
- 📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246
- 📍 Sector-88, Faridabad, Haryana-121002
- 📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009
- 📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001

Annexure B

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations'), read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Sr. No.	Details of Events	Information of such events(s)
a)	Reason for change viz., appointment, resignation, removal, death or otherwise;	Re-appointment of M/s Subodh Kumar & Co. (SKC), Cost Accountants (Firm registration number: 104250) as the Cost Auditor of the Company, for the Financial Year 2025-26.
b)	Date of Appointment/ Re-appointment and term of Appointment/ Re-appointment	August 05, 2025, for the Financial Year 2025-26
c)	Brief profile (in case of appointment)	M/s Subodh Kumar & Co. (SKC), is a reputed firm of Cost Accountants established in November 2015, specializing in Cost Accounting, Cost Auditing, and Maintenance of Cost Records. Since its inception, SKC has built a strong reputation for delivering high-quality professional services and has consistently served a diverse clientele, including many well-established and reputed companies across various sectors.
d)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Registered Office

JA-108, DLF Tower A, Jasola District Centre, New Delhi-110025
Tel: 011-49967892

Corporate Office

HO-01, Sector-01, Greater Noida West-201306
Tel: 0120-6811236 | Email: cs@yatharthhospitals.com
Web: www.yatharthhospitals.com

Our Hospitals

- 📍 Sector-110, Noida, Uttar Pradesh-201304
- 📍 Sector Omega-01, Greater Noida, Uttar Pradesh-201308
- 📍 Sector-01, Greater Noida West, Uttar Pradesh-201306
- 📍 Jhansi Mauranipur Highway, Orchha, Madhya Pradesh-472246
- 📍 Sector-88, Faridabad, Haryana-121002
- 📍 4C Institutional Area, North Extension, Model Town 3, New Delhi-110009
- 📍 Plot No. 9 & 9A, Sector 20B, Faridabad, Haryana-121001



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of **Yatharth Hospital & Trauma Care Services Limited** pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of
Yatharth Hospital & Trauma Care Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Company) for the quarter ended June 30, 2025 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A



review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements.

5. Other Matter

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31,2025 and the published un-audited year to date figures up to December 31,2024, which were subjected to a limited review by us, as required under the Listing Regulations.

Our conclusion is not modified in respect of above matter.

For R. Nagpal Associates


Chartered Accountants

Firm Registration No. 002626N


(CA. Rohit Mehra)

Partner

Membership No. 093910



UDIN: 25093910BHIUJN4872

Place: Noida

Date: 05th August 2025

YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED
 Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: www.yatharthhospitals.com

Email: cs@yatharthhospitals.com

CIN : L85110DL2008PLC174706

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. in Million except Shares and EPS)

Particulars	Standalone			
	Quarter Ended			Year Ended
	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
	Unaudited	Audited#	Unaudited	Audited
I Revenue from operations	1,301.44	1,119.92	1,189.64	4,542.41
II Other income	72.59	40.98	26.28	116.93
III Total Income (I+II)	1,374.03	1,160.90	1,215.92	4,659.33
IV Expenses				
Medical consumables and pharmacy items consumed	281.91	231.83	249.35	878.86
Employee benefits expense	235.38	213.91	188.01	823.89
Finance costs	1.57	1.53	1.08	6.16
Depreciation and amortisation	46.87	47.09	39.95	186.63
Other expenses	433.61	356.43	424.46	1,569.48
Total expenses (IV)	999.34	850.78	902.83	3,465.02
V Profit / (loss) before exceptional items and tax (III-IV)	374.69	310.12	313.09	1,194.31
VI Exceptional items (net)(Gain)/Loss		-	-	
VII Profit / (loss) before tax (V-VI)	374.69	310.12	313.09	1,194.31
VIII Tax expense				
(1) Current tax	101.65	89.50	81.69	314.91
(2) Income tax of earlier years	-	-	-	(0.21)
(3) Reversal of MAT credit entitlement of earlier years	-	-	-	-
(4) Deferred tax	1.82	1.67	(0.07)	2.69
Total tax (VIII)	103.47	91.16	81.61	317.39
IX Net Profit/(loss) after tax (VII-VIII)	271.22	218.96	231.48	876.92
X Other Comprehensive Income				
A (i) Items that will be reclassified to profit or loss				
(ii) Income tax relating to items that will be reclassified to profit or loss				
B (i) Items that will not be reclassified to profit or loss	(0.84)	2.06		2.20
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.21	(0.52)		(0.55)
Other comprehensive income for the period	(0.63)	1.54	-	1.65
XI Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)	270.59	220.50	231.48	878.57
XII Other equity				14,287.94
XIII Earnings Per Share (Rs.10 each)				
(Not annualised except for the year ended 31 March 2024)				
Basic	2.81	2.55	2.70	9.89
Diluted	2.81	2.55	2.70	9.89
Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	963.54	963.54	858.50	963.54

#refer note no 7 of the accompanying financial results.

EPS is calculated based on Weighted Average Number of Shares.



Notes to accounts on the Un-audited standalone financial results of Yatharth Hospital & Trauma Care Services Limited for the Quarter ended June 30th, 2025:

1. The Un-audited standalone financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited for the Quarter ended June 30th, 2025, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 5th, 2025.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in the India and it constitutes the single geographical segment.
4. The Company's revenue from Medical and Healthcare services comprise of income from hospital services and sale of pharmacy items. The Company earns almost all of its revenue from hospital services. The income from sale of food items and rentals are ancillary and thus in terms of IND AS 108, no separate reporting under segment reporting is required.
5. During October 2023, The Income Tax Department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any significant tax liability on the Company.

Also the department had ordered for provisional attachment under Section 281B of the IT Act, of (i) 20,714,727 unquoted equity shares of face value ₹10 each of AKS; (ii) 5,622,950 unquoted equity shares of face value ₹10 of Sanskar Medica India Limited; (iii) 4,010,000 unquoted equity shares of face value ₹10 of Ramraja; and (iv) 45,000,980 unquoted equity shares of face value ₹10 of Pristine Infracon Private Limited, held by our Company and group properties located at (a) Plot No. NH 32, Sector Omega I, Greater Noida, Uttar Pradesh, India; (b) NH-01, Sector 110, Noida, Gautam Budh Nagar, Uttar Pradesh, India; (c) Jhansi Mauranipur Highway, Near Orchha Tigaila Orchha, Tikamgarh, Pratap Pura, Madhya Pradesh; and (d) Plot No. HO-01, Sector 1, Greater Noida (West), Uttar Pradesh, India and prohibited the holder/ owner from transferring/ parting with such property from the date of such respective orders in order to protect its interest.

6. During the FY 2023-24, the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 Equity Shares aggregating to ₹ 4,900.00 million by our Company ("Fresh Issue") Offer for sale of 6,551,690 Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders ("Offer for Sale"). Further Company has undertaken a Pre-IPO Placement by way



of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of the Board dated July 6, 2023. The size of the Fresh Issue of Equity Shares has been adjusted to ₹ 4,900.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7th August 2023.

The utilization of the IPO is summarized below:

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized in Rs. Million			
			As at beginning of the quarter	During the quarter	At the end of the quarter	Balance as on 30.06.2025
1	Repayment, in full or part, of certain borrowings availed by the company	1000.00	1,000.00	-	1,000.00	-
2	Repayment, in full or part, of certain borrowings availed by the subsidiaries, AKS and Ramraja	1450.00	1,427.20	-	1,427.20	22.80
3	Funding capital expenditure, expenses of two hospitals namely Noida and Greater Noida Hospital	256.40	256.40	-	256.40	-
4	Funding capital expenditure, expenses of subsidiaries; AKS and Ramraja for respective hospital operated by them	1069.70	562.97	-	562.97	506.73
5	Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	650.00	-	650.00	-
6	General Corporate Purpose	1271.00	1,234.43	-	1,234.43	36.57
	Total	5697.10	5,131.00	-	5,131.00	566.10




7. During the previous financial year FY 2024-25, the Company raised further funds from Qualified Institutional buyers (QIB) in qualified institutional placements. In QIP Fresh issue of 105,04,124 Equity Shares issued at a price of Rs. 595/- for amount aggregating to ₹ 6249.95 million was made by Company ("Fresh Issue").

The utilization of the QIP is summarized below:

(amount in million)

Object(s)	Amount as per final offer document	Amount utilized at the beginning of the reported quarter	Amount utilized during the reported quarter	Amount utilized at the end of the reported quarter	Total unutilized amount as at 30-06-2025
Repayment / pre-payment, in full or in part, of certain outstanding borrowings availed by: Company and Subsidiary	956.80	956.80	-	956.80	-
Funding in part the acquisition costs of two hospitals situated at Model Town, Delhi and Faridabad, Haryana	2173.85	2015.88	147.29	2163.17	10.68
Funding for purchase of medical equipment's	1517.36	47.10	353.46	400.56	1116.80
General corporate purposes	1390.99	659.85	412.98	1072.83	318.16
Sub-total	6039.00	3679.63	913.73	4593.37	1445.64
Issue expenses	210.95	210.95	-	210.95	-
Total proceeds from QIP	6249.95	3890.58	913.73	4804.32	1445.64



8. The Company had participated in an e-auction under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act of 2002 (“SARFAESI Act”) conducted by Union Bank of India on October 29, 2024, for purchase of (i) a leasehold land building, which is a hospital located at Plot No. 4C, Institutional Area, Model Town - III, Shahid Ram Prasad Bismil Marg Delhi 110009, India, admeasuring to 8,000 square meters, comprising of four-story hospital building with two basement floors; and (ii) hypothecated plant and machinery present inside the hospital premises as movable and immovable item, under *pari passu* charge with Union Bank of India (collectively “Scheduled Property”). Subsequently, the sale confirmation letter dated October 30, 2024, was issued by Union Bank of India to our Company.

Accordingly, Company had paid entire Sale Consideration in permitted trenches. The final letter was received from Union Bank of India on 15.03.2025 and the registration of property has been done on 28th March 2025. The company inaugurated its facility on 14th July 2025 and commenced commercial operations.

9. Previous period/ year figures have been regrouped/ reclassified, wherever necessary, to make them comparable
10. The aforesaid Statement is available on the Holding Company's website (www.yatharthhospitals.in) and on the website of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

On behalf of the Board of Directors
Yatharth Hospital & Trauma Care Services Ltd.
Dr. Ajay Kumar Tyagi



Chairman and Whole-time Director
Place: Noida
Dated: 05/08/2025



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of **Yatharth Hospital & Trauma Care Services Limited** pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of
Yatharth Hospital & Trauma Care Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Holding Company) and its subsidiaries (The Holding Company and its Subsidiaries together referred to as 'the Group') for the quarter ended June 30 , 2025 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting"("IND AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of




persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulation, to the extent applicable.

4. The Statement includes the results of the following Subsidiaries:
- (i) AKS Medical & Research Centre Private Limited
 - (ii) Ramraja Multispeciality Hospital & Trauma Centre Private Limited
 - (iii) Sanskar Medica India Limited
 - (iv) Pristine Infracon Private Limited
 - (v) MGS Infotech Research and Solutions Private Limited

We did not review the financial results of Five subsidiaries included in the consolidated financial results whose financial results reflect Total revenues of Rs. 1,303.37 Millions, for the quarter ended 30th June 2025, total Net Profit after tax of Rs. 153.37 Millions for the quarter ended 30th June 2025 and total comprehensive income of Rs. 151.96 Millions for the quarter ended 30th June 2025 respectively, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our Conclusion on above matter is not modified.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the




Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements.

6. Other Matter

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published un-audited year to date figures up to December 31, 2024, which were subjected to a limited review by us, as required under the Listing Regulations.

Our conclusion is not modified in respect of above matter

For R. Nagpal Associates
Chartered Accountants
Firm Registration No. 002626N


(CA. Rohit Mehra)
Partner
Membership No. 093910



UDIN: 25093910BM1U307037
Place: Noida
Date: 05th August 2025

YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED
 Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: www.yatharthhospitals.com

Email: cs@yatharthhospitals.com

CIN : L85110DL2008PLC174706

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

(Rs. in Million except Shares and EPS)

Particulars	Consolidated			
	Quarter Ended		Year Ended	
	30-Jun-25 Unaudited	31-Mar-25 Audited#	30-Jun-24 Unaudited	31-Mar-25 Audited
I Revenue from operations	2,577.71	2,317.81	2,117.83	8,804.87
II Other income	93.11	53.41	36.53	161.75
III Total Income (I+II)	2,670.82	2,371.22	2,154.36	8,966.62
IV Expenses				
Medical consumables and pharmacy items consumed	535.12	464.97	468.04	1,785.29
Employee benefits expense	481.77	438.20	346.07	1,625.00
Finance costs	1.90	9.72	29.17	75.11
Depreciation and amortisation	149.19	128.70	114.43	571.72
Other expenses	915.96	844.32	767.07	3,192.11
Total expenses (IV)	2,083.93	1,885.91	1,724.78	7,249.22
V Profit / (loss) before exceptional items and tax (III-IV)	586.89	485.31	429.58	1,717.39
VI Exceptional items (net)(Gain)/Loss	-	-	-	-
VII Profit / (loss) before tax (V-VI)	586.89	485.31	429.58	1,717.39
VIII Tax expense				
(1) Current tax	146.06	137.55	136.10	491.62
(2) Income tax of earlier years	-	-	-	(0.19)
(3) Reversal of MAT credit entitlement of earlier years	-	-	-	-
(4) Deferred tax	20.42	(39.47)	(10.35)	(79.54)
Total tax (VIII)	166.48	98.08	125.74	411.89
IX Net Profit/(loss) after tax (VII-VIII)	420.41	387.23	303.84	1,305.50
X Other Comprehensive Income				
A (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
B (i) Items that will not be reclassified to profit or loss	(2.45)	2.88	-	3.91
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.62	(0.72)	-	(0.98)
Other comprehensive income for the period	(1.83)	2.16	-	2.93
XI Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)	418.58	389.39	303.84	1,308.43
Profit/(Loss) for the year attributable to:				
To the Owners of the company	420.37	387.18	303.84	1,305.45
Non Controlling Interest	0.04	0.05	-	0.05
Other comprehensive income for the period/year attributable to:				
To the Owners of the company	(1.83)	2.16	-	2.93
Non Controlling Interest	-	-	-	-
Total Comprehensive Income for the period attributable to:				
To the Owners of the company	418.54	389.34	303.84	1,308.38
Non Controlling Interest	0.04	0.05	-	0.05
XII Other equity				15,091.05
XIII Earnings Per Share (Rs.10 each)				
(Not annualised except for the year ended 31 March 2024)				
Basic	4.36	4.37	3.54	14.72
Diluted	4.36	4.37	3.54	14.72
Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	963.54	963.54	858.50	963.54

EPS is calculated based on Weighted Average Number of Shares.




Notes to accounts on the Un-audited Consolidated Financial Results of Yatharth Hospital & Trauma Care Services Limited for the Quarter ended June 30th, 2025:

1. The Un-audited consolidated financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited ('the Holding Company') along with its subsidiaries for the Quarter ended June 30th, 2025, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 5th, 2025.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in the India and it constitutes the single geographical segment.
4. The Company's revenue from Medical and Healthcare services comprise of income from hospital services and sale of pharmacy items. The Company earns almost all of its revenue from hospital services. The income from sale of food items and rentals are ancillary and thus in terms of IND AS 108, no separate reporting under segment reporting is required.
5. During October 2023, The Income Tax Department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any significant tax liability on the Company.

Also the department had ordered for provisional attachment under Section 281B of the IT Act, of (i) 20,714,727 unquoted equity shares of face value ₹10 each of AKS; (ii) 5,622,950 unquoted equity shares of face value ₹10 of Sanskar Medica India Limited; (iii) 4,010,000 unquoted equity shares of face value ₹10 of Ramraja; and (iv) 45,000,980 unquoted equity shares of face value ₹10 of Pristine Infracon Private Limited, held by our Company and group properties located at (a) Plot No. NH 32, Sector Omega I, Greater Noida, Uttar Pradesh, India; (b) NH-01, Sector 110, Noida, Gautam Budh Nagar, Uttar Pradesh, India; (c) Jhansi Mauranipur Highway, Near Orchha Tigaila Orchha, Tikamgarh, Pratap Pura, Madhya Pradesh; and (d) Plot No. HO-01, Sector 1, Greater Noida (West), Uttar Pradesh, India and prohibited the holder/ owner from transferring/ parting with such property from the date of such respective orders in order to protect its interest.

The subsidiary group, i.e AKS Medical & Research Centre Private Limited, has revised its ITR in response to notice under section 148 of the Income Tax act for assessment year 2021-22 & 22-23 and has deposited a sum of Rs 5.00 million & 7.38 million as additional tax on 29th April 2025.



6. During the FY 2023-24, the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 Equity Shares aggregating to ₹ 4,900.00 million by our Company (“Fresh Issue”) Offer for sale of 6,551,690 Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders (“Offer for Sale”). Further Company has undertaken a Pre-IPO Placement by way of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of the Board dated July 6, 2023. The size of the Fresh Issue of Equity Shares has been adjusted to ₹ 4,900.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7th August 2023.

The utilization of the IPO is summarized below:

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized in Rs. Million			
			As at beginning of the quarter	During the quarter	At the end of the quarter	Balance as on 30.06.2025
1	Repayment, in full or part, of certain borrowings availed by the company	1000.00	1,000.00	-	1,000.00	-
2	Repayment, in full or part, of certain borrowings availed by the subsidiaries, AKS and Ramraja	1450.00	1,427.20	-	1,427.20	22.80
3	Funding capital expenditure, expenses of two hospitals namely Noida and Greater Noida Hospital	256.40	256.40	-	256.40	-
4	Funding capital expenditure, expenses of subsidiaries; AKS and Ramraja for respective hospital operated by them	1069.70	562.97	-	562.97	506.73
5	Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	650.00	-	650.00	-
6	General Corporate Purpose	1271.00	1,234.43	-	1,234.43	36.57
	Total	5697.10	5,131.00	-	5,131.00	566.10

Ag-




7. During the previous financial year FY 2024-25, the Company raised further funds from Qualified Institutional buyers (QIB) in qualified institutional placements. In QIP fresh issue of 105,04,124 Equity Shares issued at a price of 595.00 per equity share for amount aggregating to ₹ 6249.95 million was made by Company (“Fresh Issue”).

The utilization of the QIP is summarized below:

Object(s)	Amount as per final offer document	Amount utilized at the beginning of the reported quarter	Amount utilized during the reported quarter	Amount utilized at the end of the reported quarter	Total unutilized amount as at the end of the reported quarter
Repayment / pre-payment, in full or in part, of certain outstanding borrowings availed by: Company and Subsidiary	956.80	956.80	-	956.80	-
Funding in part the acquisition costs of two hospitals situated at Model Town, Delhi and Faridabad, Haryana	2173.85	2015.88	147.29	2163.17	10.68
Funding for purchase of medical equipment's	1517.36	47.10	353.46	400.56	1116.80
General corporate purposes	1390.99	659.85	412.98	1072.83	318.16
Sub-total	6039.00	3679.63	913.73	4593.37	1445.64
Issue expenses	210.95	210.95	-	210.95	-
Total	6249.95	3890.58	913.73	4804.32	1445.64

8. The Company had participated in an e-auction under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act of 2002 (“SARFAESI Act”) conducted by Union Bank of India on October 29, 2024, for purchase of (i) a leasehold land building, which is a hospital located at Plot No. 4C, Institutional Area, Model Town - III, Shahid Ram Prasad Bismil Marg Delhi 110009, India, admeasuring to 8,000 square meters, comprising of four-story hospital building with two basement floors; and (ii) hypothecated plant and machinery present inside the hospital premises as movable and immovable item, under *pari passu* charge with Union



Bank of India (collectively "Scheduled Property"). Subsequently, the sale confirmation letter dated October 30, 2024, was issued by Union Bank of India to our Company.

Accordingly, Company had paid entire Sale Consideration in permitted trenches. The final letter was received from Union Bank of India on 15.03.2025 and the registration of property has been done on 28th March 2025. The company inaugurated its facility on 14th July 2025 and commenced commercial operations.

9. The company plans to commence the commercial operations soon at MGS Infotech Research and Solutions Private Limited Faridabad, Haryana, a subsidiary company.
10. In respect of subsidiary company i.e. Ramraja Hospital & Trauma Centre Pvt Ltd. an order from Divisional Commissioner of Sagar, Madhya Pradesh, was received to take over the hospital premises, as the land stated in the order belonged to the State of Madhya Pradesh. In respect of the writ petition filed by the company, the honorable high court of Madhya Pradesh has set aside the order passed by the divisional commissioner of Sagar and the company was directed to appear before the commissioner Sagar on 11th November 2024. Vide order dated 30th June 2025, the Commissionerate has officially set aside their earlier order thereby confirming the company's rightful claim to the land.
11. The aforesaid Statement is available on the Holding Company's website (www.yatharthhospitals.in) and on the website of the Stock Exchanges (www.bseindia.com and www.nseindia.com).

On behalf of the Board of Directors

Yatharth Hospital & Trauma Care Service Ltd

Dr. Ajay Kumar Tyagi
Chairman and Whole-time Director

Place: Noida

Dated: 05/08/2025

